Leerink Partnrs Has Positive Outlook of IONS FY2025 Earnings

Key Points

• Leerink Partnrs has raised its FY2025 earnings estimate for Ionis Pharmaceuticals to ($2.78) per share, an improvement from the previous forecast of ($2.79).
• Ionis Pharmaceuticals reported a significant increase in revenue of 100.9% year-over-year, with quarterly earnings of $0.70 EPS, surpassing consensus estimates.
• Analysts have varied price targets for the stock, with a consensus rating of "Moderate Buy" and an average target price of $67.88.

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) - Leerink Partnrs lifted their FY2025 earnings per share (EPS) estimates for shares of Ionis Pharmaceuticals in a report issued on Monday, September 15th. Leerink Partnrs analyst M. Foroohar now expects that the company will post earnings per share of ($2.78) for the year, up from their previous estimate of ($2.79). The consensus estimate for Ionis Pharmaceuticals' current full-year earnings is ($3.50) per share. Leerink Partnrs also issued estimates for Ionis Pharmaceuticals' Q4 2025 earnings at ($1.42) EPS.

Ionis Pharmaceuticals (NASDAQ:IONS - Get Free Report) last issued its quarterly earnings data on Wednesday, July 30th. The company reported $0.70 earnings per share for the quarter, beating analysts' consensus estimates of $0.19 by $0.51. The firm had revenue of $452.00 million during the quarter, compared to analyst estimates of $270.90 million. Ionis Pharmaceuticals had a negative return on equity of 45.29% and a negative net margin of 28.25%.The business's quarterly revenue was up 100.9% compared to the same quarter last year. During the same quarter last year, the business posted ($0.45) earnings per share. Ionis Pharmaceuticals has set its FY 2025 guidance at EPS.

IONS has been the subject of several other research reports. Raymond James Financial raised their price target on shares of Ionis Pharmaceuticals from $60.00 to $64.00 and gave the company a "strong-buy" rating in a research report on Thursday, July 31st. Morgan Stanley raised shares of Ionis Pharmaceuticals from an "equal weight" rating to an "overweight" rating and boosted their price objective for the company from $55.00 to $62.00 in a research report on Thursday, July 31st. Stifel Nicolaus set a $43.00 price target on shares of Ionis Pharmaceuticals in a research report on Thursday, August 21st. Jefferies Financial Group increased their price objective on shares of Ionis Pharmaceuticals from $83.00 to $96.00 and gave the stock a "buy" rating in a research report on Tuesday, September 2nd. Finally, HC Wainwright increased their price objective on shares of Ionis Pharmaceuticals from $70.00 to $95.00 and gave the company a "buy" rating in a research note on Tuesday, September 2nd. One research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $67.88.

Ionis Pharmaceuticals Stock Performance

NASDAQ:IONS traded down $0.73 during mid-day trading on Wednesday, hitting $61.01. The company's stock had a trading volume of 3,305,121 shares, compared to its average volume of 3,198,900. The business's fifty day moving average is $47.72 and its two-hundred day moving average is $38.44. The company has a debt-to-equity ratio of 0.99, a current ratio of 2.87 and a quick ratio of 2.86. Ionis Pharmaceuticals has a 1 year low of $23.95 and a 1 year high of $64.71. The stock has a market cap of $9.72 billion, a price-to-earnings ratio of -33.16 and a beta of 0.28.

Insider Activity at Ionis Pharmaceuticals

In other news, EVP Patrick R. O'neil sold 76,850 shares of the business's stock in a transaction that occurred on Wednesday, September 3rd. The stock was sold at an average price of $60.97, for a total transaction of $4,685,544.50. Following the transaction, the executive vice president directly owned 5,655 shares of the company's stock, valued at approximately $344,785.35. The trade was a 93.15% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Eugene Schneider sold 19,658 shares of the business's stock in a transaction on Wednesday, September 3rd. The stock was sold at an average price of $60.81, for a total value of $1,195,402.98. Following the completion of the transaction, the executive vice president owned 51,507 shares of the company's stock, valued at $3,132,140.67. This represents a 27.62% decrease in their position. The disclosure for this sale can be found here. Insiders sold 492,841 shares of company stock valued at $28,595,925 over the last three months. 2.60% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Allworth Financial LP lifted its position in Ionis Pharmaceuticals by 231.8% during the 2nd quarter. Allworth Financial LP now owns 740 shares of the company's stock worth $29,000 after acquiring an additional 517 shares during the period. Signaturefd LLC grew its position in shares of Ionis Pharmaceuticals by 45.6% in the first quarter. Signaturefd LLC now owns 1,382 shares of the company's stock valued at $42,000 after purchasing an additional 433 shares in the last quarter. Ancora Advisors LLC acquired a new position in Ionis Pharmaceuticals in the first quarter valued at approximately $60,000. CWM LLC lifted its holdings in Ionis Pharmaceuticals by 18.7% in the first quarter. CWM LLC now owns 2,435 shares of the company's stock valued at $73,000 after acquiring an additional 384 shares during the last quarter. Finally, Parallel Advisors LLC lifted its stake in Ionis Pharmaceuticals by 151.3% during the second quarter. Parallel Advisors LLC now owns 1,872 shares of the company's stock worth $74,000 after purchasing an additional 1,127 shares in the last quarter. 93.86% of the stock is currently owned by hedge funds and other institutional investors.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.